134 related articles for article (PubMed ID: 11354371)
1. Synthesis and evaluation of efavirenz (Sustiva) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain.
Cocuzza AJ; Chidester DR; Cordova BC; Jeffrey S; Parsons RL; Bacheler LT; Erickson-Viitanen S; Trainor GL; Ko SS
Bioorg Med Chem Lett; 2001 May; 11(9):1177-9. PubMed ID: 11354371
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).
Patel M; McHugh RJ; Cordova BC; Klabe RM; Erickson-Viitanen S; Trainor GL; Ko SS
Bioorg Med Chem Lett; 1999 Nov; 9(22):3221-4. PubMed ID: 10576692
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors.
Patel M; Ko SS; McHugh RJ; Markwalder JA; Srivastava AS; Cordova BC; Klabe RM; Erickson-Viitanen S; Trainor GL; Seitz SP
Bioorg Med Chem Lett; 1999 Oct; 9(19):2805-10. PubMed ID: 10522695
[TBL] [Abstract][Full Text] [Related]
4. 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
Cocuzza AJ; Chidester DR; Cordova BC; Klabe RM; Jeffrey S; Diamond S; Weigelt CA; Ko SS; Bacheler LT; Erickson-Viitanen SK; Rodgers JD
Bioorg Med Chem Lett; 2001 Jun; 11(11):1389-92. PubMed ID: 11378361
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
Corbett JW; Ko SS; Rodgers JD; Gearhart LA; Magnus NA; Bacheler LT; Diamond S; Jeffrey S; Klabe RM; Cordova BC; Garber S; Logue K; Trainor GL; Anderson PS; Erickson-Viitanen SK
J Med Chem; 2000 May; 43(10):2019-30. PubMed ID: 10821714
[TBL] [Abstract][Full Text] [Related]
6. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
Maga G; Ubiali D; Salvetti R; Pregnolato M; Spadari S
Antimicrob Agents Chemother; 2000 May; 44(5):1186-94. PubMed ID: 10770750
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and pharmacological evaluation of HIV-1 reverse transcriptase inhibition of new indolin-2-ones.
Boechat N; Kover WB; Bongertz V; Bastos MM; Romeiro NC; Azevedo ML; Wollinger W
Med Chem; 2007 Nov; 3(6):533-42. PubMed ID: 18045202
[TBL] [Abstract][Full Text] [Related]
8. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant.
Lindberg J; Sigurdsson S; Löwgren S; Andersson HO; Sahlberg C; Noréen R; Fridborg K; Zhang H; Unge T
Eur J Biochem; 2002 Mar; 269(6):1670-7. PubMed ID: 11895437
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
Gawali R; Trivedi J; Bhansali S; Bhosale R; Sarkar D; Mitra D
Eur J Med Chem; 2018 Sep; 157():310-319. PubMed ID: 30099253
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
Romines KR; Freeman GA; Schaller LT; Cowan JR; Gonzales SS; Tidwell JH; Andrews CW; Stammers DK; Hazen RJ; Ferris RG; Short SA; Chan JH; Boone LR
J Med Chem; 2006 Jan; 49(2):727-39. PubMed ID: 16420058
[TBL] [Abstract][Full Text] [Related]
12. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz.
Bosch RJ; Downey GF; Katzenstein DA; Hellmann N; Bacheler L; Albrecht MA;
AIDS; 2003 Nov; 17(16):2395-6. PubMed ID: 14571193
[No Abstract] [Full Text] [Related]
14. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of a series of thioamides as non-nucleoside reverse transcriptase inhibitors.
Mehanna AS; Belani JD; Kelley CJ; Pallansc LA
Med Chem; 2007 Nov; 3(6):513-9. PubMed ID: 18045200
[TBL] [Abstract][Full Text] [Related]
16. QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Duchowicz PR; Fernández M; Caballero J; Castro EA; Fernández FM
Bioorg Med Chem; 2006 Sep; 14(17):5876-89. PubMed ID: 16766190
[TBL] [Abstract][Full Text] [Related]
17. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
[TBL] [Abstract][Full Text] [Related]
18. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
Rodríguez-Barrios F; Balzarini J; Gago F
J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
[TBL] [Abstract][Full Text] [Related]
19. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
20. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
